Lead / Lab Manager: Reviews method suitability and assigns instrumentation and personnel.

Quality Assurance: Ensures that documentation and process adhere to regulatory standards.

4. Accountability

The Head of Bioanalytical Department is accountable for ensuring compliance, resource availability, and approval of finalized methods.

5. Procedure

5.1 Pre-Development Review

1. Review the study protocol, Investigator’s Brochure, and product-specific regulatory guidance (e.g., FDA, EMA).
2. Assess:
   • Analyte(s) of interest and their physicochemical properties
   • Concentration range and matrix of interest
   • Required sensitivity, specificity, and regulatory expectations
3. Document pre-development review in Annexure-1: Method Development Planning Form.

5.2 Selection of Analytical Technique

1. Choose the appropriate platform (e.g., LC-MS/MS, HPLC-UV) based on:
   • Analyte ionization potential
   • Required LLOQ and sample volume
   • Matrix complexity
2. Verify availability of instruments and columns.

5.3 Optimization of Sample Preparation

1. Select suitable extraction technique:
   • Protein precipitation
   • Liquid-liquid extraction (LLE)
   • Solid-phase extraction (SPE)
2. Evaluate extraction recovery and matrix interference using at least 6 lots of blank plasma.
3. Record findings in Annexure-2: Extraction Optimization Log.

5.4 Chromatographic Conditions

1. Develop chromatographic method:
   • Mobile phase selection and gradient optimization
   • Column selection (C18, HILIC, etc.)
   • Flow rate, temperature, and injection volume
2. Target retention time, peak symmetry, and baseline separation.
3. Maintain Annexure-3: Chromatography Method Log.

5.5 Detection and Mass Spectrometry Optimization

1. Optimize ionization mode (positive/negative ESI), source parameters, and compound-dependent parameters.
2. Select appropriate transitions (precursor & product ions) for quantifier and qualifier channels.
3. Perform tuning with authentic reference standards and document parameters in Annexure-4.

5.6 Calibration Range and LLOQ Assessment

1. Prepare calibration standards and evaluate:
   • Linearity (r ≥ 0.995)
   • Accuracy within ±15% for all levels (±20% for LLOQ)
2. Evaluate signal-to-noise ratio at LLOQ level (≥ 5:1).

5.7 Internal Standard Selection

1. Select stable isotope-labeled analogs wherever available.
2. Assess retention time match and ion suppression/enhancement.

5.8 Preliminary Stability and Selectivity Testing

1. Test for selectivity using 6 different blank matrix lots.
2. Perform short-term stability at room temperature (6 hrs), freeze-thaw stability (3 cycles), and auto-sampler stability (24 hrs).
3. Record data in Annexure-5: Preliminary Stability Report.

5.9 Documentation and Review

1. Compile complete method development report including all chromatograms, calculations, and conclusions.
2. Submit for review by Team Lead and QA.
3. Obtain documented approval using Annexure-6: Method Approval Form.

6. Abbreviations

• BA/BE: Bioavailability/Bioequivalence
• LC-MS/MS: Liquid Chromatography–Tandem Mass Spectrometry
• LLOQ: Lower Limit of Quantification
• HPLC: High-Performance Liquid Chromatography
• ESI: Electrospray Ionization
• QA: Quality Assurance

7. Documents

1. Method Development Planning Form – Annexure-1
2. Extraction Optimization Log – Annexure-2
3. Chromatography Method Log – Annexure-3
4. MS Parameter Optimization Sheet – Annexure-4
5. Preliminary Stability Report – Annexure-5
6. Method Approval Form – Annexure-6

8. References

• ICH M10 – Bioanalytical Method Validation Guidelines
• US FDA Guidance for Industry: Bioanalytical Method Validation
• EMA Guideline on Bioanalytical Method Validation

9. SOP Version

Version: 2.0

10. Approval Section

	Prepared By	Checked By	Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: Method Development Planning Form

Analyte	XYZ-123
Matrix	Human plasma
Concentration Range	1 – 1000 ng/mL
Analytical Technique	LC-MS/MS
Prepared By	Rajesh Kumar

Annexure-2: Extraction Optimization Log

Technique	Recovery (%)	Matrix Effect	Selected
Protein Precipitation	85%	Low	Yes
LLE	70%	Moderate	No

Annexure-3: Chromatography Method Log

Mobile Phase	Column	RT (min)	Remarks
ACN:Water (0.1% FA)	C18 50 mm	3.5	Acceptable

Annexure-4: MS Parameter Optimization

Precursor Ion	Product Ion	DP (V)	CE (eV)	RT
301.2	123.1	50	25	3.4 min

Annexure-5: Preliminary Stability Report

Condition	Result	Remarks
Room Temp (6h)	98%	Stable
Freeze-Thaw (3 cycles)	95%	Stable

Annexure-6: Method Approval Form

Method Name	XYZ-123 Plasma Quantitation
Approved By	Sunita Reddy
Approval Date	17/04/2025

Revision History:

Revision Date	Revision No.	Details	Reason	Approved By
01/01/2022	1.0	Initial release	New SOP	QA Head
17/04/2025	2.0	Included updated method development flow and annexures	Compliance with ICH M10	QA Head